DC260126
CAS: 346692-04-4
Ref. 3D-WNA69204
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen | ||
50mg | Ausgelaufen | ||
100mg | Ausgelaufen |
Produktinformation
DC260126 is an investigational drug for the treatment of human breast cancer. DC260126 is a G-protein coupled receptor agonist that increases energy metabolism and insulin secretion from β-cells in the pancreas. This drug has been shown to reduce atp levels in human serum and increase cytosolic Ca2+ concentrations in cancer cells. DC260126 also has anti-inflammatory properties, which may be due to its ability to inhibit prostaglandin synthesis. It has been shown to decrease hepatic steatosis, which can cause metabolic disorders such as diabetes mellitus type 2 and insulin resistance. DC260126 has potential as a drug target for diseases related to mitochondrial dysfunction, such as Alzheimer's disease and Parkinson's disease.